Life science and clinical diagnostic firm Bio-Rad Laboratories has launched its new CFX Opus 384 Dx System and CFX Opus 96 Dx System. The two devices provide real-time PCR detection, with precise quantification helping to deliver improved efficiencies and assay development, as well as greater productivity in diagnostic testing and research.
The systems have already been listed with the US regulator the Food and Drug Administration (FDA) and also meet European CE-IVD requirements. The systems have also both been registered with the necessary regulatory bodies in Canada and Singapore.
The two systems, the latest in the Bio-Rad Laboratories' line of real-time PCR systems, can provide efficient assay development for up to five targets. The systems have integrated security capabilities, thermal cycler performance and straightforward desktop management.
Bio-Rad’s Director for Gene Expression and Software Tech Steven Blakely said: “We continue to see an increasing demand for real-time PCR systems that offer more efficient workflows and improved data management and analysis that meets regulatory requirements in IVD assay development and testing, and we’re pleased to introduce the CFX Opus Dx Detection Systems to meet these needs.”
“Both systems are robust and secure platforms that leverage Bio-Rad’s long-standing expertise in genomic tools to better serve both research and clinical diagnostic markets.”